Richmond Pharmacology is pleased to confirm its involvement in the Amyloidosis Conference 2025 in Italy, an important international meeting dedicated to advancing understanding and treatment of systemic amyloidosis.
The conference will bring together leading clinicians, researchers, and industry experts to share the latest insights in disease mechanisms, diagnostic advances, and emerging therapeutic strategies.
Representing Richmond Pharmacology:
• Dr Jörg Täubel, Chief Executive Officer
Dr Täubel is eager to engage with peers and collaborators to identify opportunities in:
• Early-phase trials in rare and metabolic diseases
• Clinical development strategies for amyloidosis therapies
• Regulatory advice and scientific engagement
• Patient recruitment in rare disease populations
• Adaptive and patient-focused trial design
If you are attending the Amyloidosis Conference and would like to learn how Richmond Pharmacology can support your amyloidosis or rare disease clinical development, we welcome you to connect with us during the event.
For meeting requests or collaboration enquiries:
📧info@richmondpharmacology.com
Learn more about the event: ATTR meeting 2025- Amyloidosis Alliance
.svg){kind=small}
-min.jpg)
.jpg)
